Clinical Trials Logo

Clinical Trial Summary

The study will evaluate the efficacy and safety of BM32 in grass pollen allergic subjects. It will test the hypothesis that either of two doses of BM32 will lead to a sustained relief off allergy symptoms over a two year study period.


Clinical Trial Description

The present study is designed to evaluate the efficacy and safety of a treatment with the recombinant vaccine BM32 during two consecutive grass pollen seasons. Efficacy evaluation will be performed on the basis of allergy symptoms and use of relief medication as well as based on immunological parameters. After patient assessment during a screening season, patients will be randomized to one of two doses of BM32 or placebo. Patients will receive three injections of BM32 pre-season and one post-season boost injection to maintain optimal allergen specific IgG responses. Outcome will be measured after both seasons individually. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01538979
Study type Interventional
Source Biomay AG
Contact
Status Completed
Phase Phase 2
Start date March 2012
Completion date March 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05560698 - A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment N/A
Completed NCT01445002 - Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy Phase 2
Completed NCT01830673 - Regulatory T-cells After Subcutaneous Immunotherapy N/A
Active, not recruiting NCT04502966 - Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction Phase 2
Completed NCT00263601 - Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis Phase 3
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT00264459 - Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture Phase 3
Completed NCT01308021 - Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis Phase 2
Completed NCT00773240 - A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Phase 3